Diseases » Wiskott-Aldrich Syndrome » Treatments

Treatments for Wiskott-Aldrich Syndrome

Treatments for Wiskott-Aldrich Syndrome

The list of treatments mentioned in various sources for Wiskott-Aldrich Syndrome includes the following list. Always seek professional medical advice about any treatment or change in treatment plans.

• Bone marrow transplantation
• Spleen removal
• Antibiotics
• IVIG
• Avoid allergic foods

Drugs and Medications used to treat Wiskott-Aldrich Syndrome:

Note:You must always seek professional medical advice about any prescription drug, OTC drug, medication, treatment or change in treatment plans.

Some of the different medications used in the treatment of Wiskott-Aldrich Syndrome include:

• Immune Globulin (intravenous)
• Carimune
• Carimune NF
• Flebogamma
• Gamimune N
• Gammagard S/D
• Gammar-P
• Gamunex
• Iveegam EN
• Octagam
• Panglobulin
• Panglobulin NF
• Polygam S/D
• Iveegam Immuno
• Cilax
• Intacglobin
• Sandoblobulina

Buy Products Related to Treatments for Wiskott-Aldrich Syndrome

Book Excerpts: Treatment of Wiskott-Aldrich Syndrome

• Treatment - Thrombocytopenia
• Treatment - Atopic dermatitis
• Treatment - Thrombocytopenia
• Treatment - Wiskott-Aldrich syndrome
• Treatment - Acquired immunodeficiency syndrome
• Treatment - Common variable immunodeficiency
• Treatment - Severe combined immunodeficiency disease
• Treatment - Thrombocytopenia
• Treatment - Common variable immunodeficiency
• Treatment - Human immunodeficiency virus infection
• Treatment - Severe combined immunodeficiency disease

Treatments of Wiskott-Aldrich Syndrome: Online Medical Books

16 MEDICAL BOOKS ONLINE! Review excerpts from medical books online, free, without registration, for more information about the treatments of Wiskott-Aldrich Syndrome.

Thrombocytopenia: Treatment
(In A Page: Pediatric Signs and Symptoms)

• Dependent upon etiology, severity, and presence of acute bleeding

• ITP
  –Bone marrow exam before treatment with steroids
  –Treatment with IVIG or WinRho does not need bone marrow exam
  –Platelet transfusion is ineffective in ITP but should be considered at counts <20,000 in the neonate or with life-threatening hemorrhage
  –Severe injury is unlikely if count >10,000
  –Treatment does not hasten resolution of ITP
  –About 90% of children have resolution in 3–6 months
  –Older girls more likely to become chronic

• Acute, isolated thrombocytopenia is almost never malignancy
  –Marrow exam should be done in children with chronic or complex illness or with no response to therapy

>>>

» READ BOOK EXCERPT ONLINE »

Source: In A Page: Pediatric Signs and Symptoms, 2007

Atopic dermatitis: Treatment
(Professional Guide to Diseases (Eighth Edition))

Measures to ease this chronic disorder include meticulous skin care, environmental control of offending allergens, and drug therapy. Because dry skin aggravates itching, frequent application of nonirritating topical lubricants is important, especially after bathing or showering. Minimizing exposure to allergens and irritants, such as wools and harsh detergents, also helps control symptoms.

Drug therapy involves corticosteroids and antipruritics. Active dermatitis responds well to topical corticosteroids, which should be applied immediately after bathing for optimal penetration. Oral antihistamines are commonly used to help control itching. A bedtime dose may reduce involuntary scratching during sleep. If secondary infection develops, antibiotics are necessary. A newer treatment is the use of topical immunomodulators; these agents are steroid-free and have demonstrated an 80% success rate in studies.

» READ BOOK EXCERPT ONLINE »

Source: Professional Guide to Diseases (Eighth Edition), 2005

Thrombocytopenia: Treatment
(Professional Guide to Diseases (Eighth Edition))

Treatment varies with the underlying cause and may include corticosteroids or immune globulin to increase platelet production. The treatment of choice is removal of the offending agents in drug-induced thrombocytopenia or treatment of the underlying cause. Platelet transfusions are helpful only in treating complications of severe hemorrhage.

» READ BOOK EXCERPT ONLINE »

Source: Professional Guide to Diseases (Eighth Edition), 2005

Wiskott-Aldrich syndrome: Treatment
(Professional Guide to Diseases (Eighth Edition))

Treatment aims to limit bleeding through the use of fresh, crossmatched platelet transfusions; to prevent or control infection with prophylactic or early and aggressive antibiotic therapy as appropriate; to supply passive immunity with immune globulin infusion; and to control eczema with topical corticosteroids. (Systemic corticosteroids are contraindicated because they further compromise immunity.) An antipruritic may relieve itching.

Treatment with transfer factor has provided some limited success. However, bone marrow transplantation has been remarkably successful in some patients.

» READ BOOK EXCERPT ONLINE »

Source: Professional Guide to Diseases (Eighth Edition), 2005

Acquired immunodeficiency syndrome: Treatment
(Professional Guide to Diseases (Eighth Edition))

There is no cure for either HIV or AIDS. However, significant advances have been made to help patients control signs and symptoms and impair disease progression. Because HIV can become resistant to any drug, health care professionals use combination treatments and multiple drug regimens to suppress the virus. Patients on medication remain infectious.

An effective method of treatment is highly active antiretroviral therapy (HAART). HAART aims to reduce the number of HIV particles in the blood as measured by viral load, thus increasing T-cell counts and improving the immunologic system’s functioning. A regular and vigilant medication regimen is critical or resistance will develop because HIV strains mutate and can become resistant to HAART relatively easily.

The nucleoside analogues (sometimes called reverse transcriptase inhibitors) have been the mainstay of AIDS therapy in recent years. These drugs interfere with viral reverse transcriptase, which impairs HIV’s ability to turn its ribonucleic acid into deoxyribonucleic acid for insertion into the host cell.

Antiretroviral therapy typically begins when the patient’s CD4⁺ T-cell count drops to less than 500/µl or when the patient develops an opportunistic infection. Most clinicians recommend starting the patient on a combination of these drugs in an attempt to gain the maximum benefit and to inhibit the production of resistant mutant strains of HIV. The drug combinations and dosages are then altered, depending on the patient’s response.

Increasingly, physicians are basing changes in therapy on the patient’s viral load rather than on his CD4⁺ T-cell count. Because the CD4⁺ count is influenced by the total white blood cell count, changes in the CD4⁺ count may have nothing to do with changes in the patient’s HIV status. Many physicians suggest that patients on antiretroviral therapy have their viral load checked every 3 months.

The increasing use of protease inhibitors (PIs) has greatly increased the life expectancy of patients with AIDS. These drugs block the enzyme protease, which HIV needs to produce virions, the viral particles that spread the virus to other cells. The use of PIs dramatically reduces viral load — sometimes to undetectable levels — while producing a corresponding increase in the CD4⁺ T-cell count and, because they act at a different site than nucleoside analogues, the PIs don’t produce additional adverse effects when added to a patient’s regimen.

Antiviral therapy includes the use of multiple combined drug therapies that suppress the replication of the HIV virus in the body. After antiviral therapy is initiated, treatment should be aggressive. Initially, highly active antiviral therapy, consisting of a triple drug therapy regimen — a PI and two non-nucleoside reverse transcriptase inhibitors — is recommended. In addition to these primary treatments, anti-infectives are used to combat opportunistic infections (some are used prophylactically to help patients resist opportunistic infections), and antineoplastic drugs are used to fight associated neoplasms. Supportive treatments help maintain nutritional status and relieve pain and other distressing physical and psychological symptoms.

» READ BOOK EXCERPT ONLINE »

Source: Professional Guide to Diseases (Eighth Edition), 2005

Common variable immunodeficiency: Treatment
(Professional Guide to Diseases (Eighth Edition))

Treatment and care of patients with common variable immunodeficiency are essentially the same as for those with X-linked hypogammaglobulinemia.

Injection of immune globulin (usually weekly to monthly) helps maintain the immune response. Because these injections are painful, give them deep into a large muscle mass, such as the gluteal or thigh muscles, and massage well. If the dosage is more than 1.5 ml, divide the dose and inject it into more than one site; for frequent injections, rotate the injection sites. Because immune globulin is composed primarily of IgG, the patient may also need fresh frozen plasma infusions to provide IgA and IgM.

Antibiotics are the mainstay for combating infection. Regular X-rays and pulmonary function studies help monitor lung infection; chest physiotherapy may be ordered to forestall or help clear such infection.

» READ BOOK EXCERPT ONLINE »

Source: Professional Guide to Diseases (Eighth Edition), 2005

Severe combined immunodeficiency disease: Treatment
(Professional Guide to Diseases (Eighth Edition))

Treatment aims to restore the immune response and prevent infection. Histocompatible bone marrow transplantation is the only satisfactory treatment available to correct immunodeficiency. Because bone marrow cells must be human leukocyte antigen and mixed leukocyte culture matched, the most common donors are histocompatible siblings. However, because bone marrow transplant can produce a potentially fatal graft-versus-host (GVH) reaction, newer methods of bone marrow transplant that eliminate GVH reaction (such as lectin separation and the use of monoclonal antibodies) are being evaluated.

Fetal thymus and liver transplants have achieved limited success. Immune globulin administration may also play a role in treatment. Some SCID infants have received long-term protection by being isolated in a completely sterile environment. However, this approach isn’t effective if the infant already has had recurring infections.

Gene therapy is being used to treat ADA deficiency.

» READ BOOK EXCERPT ONLINE »

Source: Professional Guide to Diseases (Eighth Edition), 2005

Thrombocytopenia: Treatment
(Handbook of Diseases)

Effective treatment varies with the underlying cause and may include corticosteroids or immune globulin to increase platelet production. When possible, treatment consists of correction of the underlying cause or, in drug-induced thrombocytopenia, removal of the offending agents. Platelet transfusions are helpful in thrombocytopenia only in treating complications of severe hemorrhage. Splenectomy may be performed in patients whose thrombocytopenia was caused by platelet destruction.

» READ BOOK EXCERPT ONLINE »

Source: Handbook of Diseases, 2003

Common variable immunodeficiency: Treatment
(Handbook of Diseases)

Patients with common variable immunodeficiency need essentially the same treatment as patients with X-linked hypogammaglobulinemia.

I.V. immune globulin (usually weekly to monthly) helps maintain immune response. Because immune globulin is made up primarily of IgG, the patient may also need fresh frozen plasma infusions to provide IgA and IgM.

Antibiotics are the mainstay for combating infection. Regular X-rays and pulmonary function studies help monitor infection in the lungs; chest physiotherapy may forestall or help clear such infection.

» READ BOOK EXCERPT ONLINE »

Source: Handbook of Diseases, 2003

Human immunodeficiency virus infection: Treatment
(Handbook of Diseases)

No cure has yet been found for the disorder; however, primary therapy for HIV infection includes three different types of antiretroviral agents:

❑ protease inhibitors (PIs), such as ritonavir, indinavir, nelfinavir, and saquinavir

❑ nucleoside reverse transcriptase inhibitors (NRTIs), such as zidovudine, didanosine, zalcitabine, lamivudine, and stavudine

❑ nonnucleoside reverse transcriptase inhibitors (NNRTIs), such as nevirapine and delavirdine.

These agents, used in various combinations, are designed to inhibit HIV viral replication. Other potential therapies include immunomodulatory agents designed to boost the weakened immune system and anti-infective and antineoplastic agents to combat opportunistic infections and associated cancers; some are used prophylactically to help patients resist opportunistic infections.

Current treatment protocols combine three agents in an effort to gain the maximum benefit with the fewest adverse reactions. Such regimens include one PI and are considered the most effective treatment. Many variations and drug interactions are under study. Combination therapy helps inhibit the production of resistant, mutant strains. Supportive treatments help maintain nutritional status and relieve pain and other distressing physical and psychological symptoms.

Many pathogens respond to anti-infective drugs but tend to recur after treatment ends. For this reason, most patients need continuous anti-infective treatment, presumably for life or until the drug is no longer tolerated or effective.

UNDER STUDY: Once-daily dosing with antiretroviral drugs, such as didanosine, efavirenz, lamivudine, and tenofovir, to increase treatment adherence to drug-resistant variants of HIV is under investigation. A combination of amprenavir, a protease inhibitor, boosted with ritonavir has been approved, and other new antiretroviral drugs are currently in development for new dosing schedules.

Zidovudine

Treatment with zidovudine has proven effective in slowing the progression of HIV infection, decreasing opportunistic infections, and prolonging survival. However, it commonly produces serious adverse reactions and toxicities. The drug is typically combined with other agents (such as lamivudine) but has also been used as a single agent for pregnant HIV-positive women.

The current recommendation is to take 100 mg every 4 hours for a total daily dose of 600 mg, or 500 mg if the patient doesn’t want to interrupt sleep. Other NRTIs, such as didanosine and zalcitabine, may also be used in combination regimens for patients who can’t tolerate or no longer respond to zidovudine.

» READ BOOK EXCERPT ONLINE »

Source: Handbook of Diseases, 2003

Severe combined immunodeficiency disease: Treatment
(Handbook of Diseases)

Restoring immune response and preventing infection are the first goals of treatment. Histocompatible bone marrow transplant is the only satisfactory treatment available to correct immunodeficiency.

Because bone marrow cells must be matched according to human leukocyte antigen and mixed leukocyte culture, the most common donors are histocompatible siblings. But bone marrow transplant can produce a potentially fatal graft-versus-host (GVH) reaction, so newer methods of bone marrow transplant that eliminate GVH reaction (such as lectin separation and the use of monoclonal antibodies) are being evaluated.

Fetal thymus and liver transplants have achieved limited success. Administration of immune globulin may also play a role in treatment. Some SCID infants have received long-term protection by being isolated in a completely sterile environment. However, this approach isn’t effective if the infant already has had recurring infections.

Gene therapy is being used for ADA deficiency.

» READ BOOK EXCERPT ONLINE »

Source: Handbook of Diseases, 2003

 » Next page: Doctors and Medical Specialists for Wiskott-Aldrich Syndrome

Rate This Website

What do you think about the features of this website? Take our user survey and have your say:

Website User Survey

Medical Tools & Articles:

Next articles:

• Doctors and Medical Specialists for Wiskott-Aldrich Syndrome
• Cure Research for Wiskott-Aldrich Syndrome
• Medical News Summaries About Wiskott-Aldrich Syndrome
• Glossary for Wiskott-Aldrich Syndrome
• Clinical Trials for Wiskott-Aldrich Syndrome

Tools & Services:

• Bookmark this page
• Take a survey relating to Wiskott-Aldrich Syndrome
• Symptom Search
• Symptom Checker
• Medical Dictionary
• Give your feedback

Medical Articles:

• Disease & Treatments Search
• Misdiagnosis Center
• Full list of interesting articles

Forums & Message Boards

• Ask or answer a question at the Boards:
• I cannot get a diagnosis. Please help.
• Tell us your medical story.
• Share your misdiagnosis story.
• What is the best treatment for my condition?
• See all the Boards.

homepage | back to top

Common Health Mistakes

Choose ... Alzheimers & Dementia Asthma Child ADHD ADHD in Adults Allergy Hypertension Bipolar Breast Cancer Celiac Disease Crohns Disease Colon Cancer Contraception Diabetes Cancer Depression Erectile Disorder Cholesterol COPD GERD Heartburn/Reflux Metabolic Syndrome Migraine/Headache Multiple Sclerosis Obesity Osteoporosis Overactive Bladder Psoriasis Sexual Disorder Sleep Disorders Smoking The Pill Ulcerative Colitis All Common Mistakes

Symptom
Checker

Choose... Fever Rash Pain Headache Fatigue Cough Other symptoms

Search Specialists by State and City

Choose... GENERAL PRACTICE CARDIAC HEALTH WOMEN'S HEALTH CANCER CARE RADIOLOGY MENTAL HEALTH PATHOLOGY EAR, NOSE, THROAT MEDICINE GENETICS NEUROLOGY DIALYSIS CARE SURGERY ORTHOPEDICS/SPORTS MEDICINE CHILDREN'S HEALTH OTHER SPECIALTIES